Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

por Tesser, John, Kafka, Shelly, DeHoratius, Raphael J., Xu, Stephen, Hsia, Elizabeth C., Turkiewicz, Anthony
Publicado no Arthritis Res Ther (2019)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2

por McInnes, Iain B, Chakravarty, Soumya D, Apaolaza, Isabel, Kafka, Shelly, Hsia, Elizabeth C, You, Yin, Kavanaugh, Arthur
Publicado no RMD Open (2019)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses...

por Smolen, Josef S, Kay, Jonathan, Matteson, Eric L, Landewé, Robert, Hsia, Elizabeth C, Xu, Stephen, Zhou, Yiying, Doyle, Mittie K
Publicado em 2014

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoi...

por Kay, Jonathan, Fleischmann, Roy, Keystone, Edward, Hsia, Elizabeth C, Hsu, Benjamin, Mack, Michael, Goldstein, Neil, Braun, Jürgen, Kavanaugh, Arthur
Publicado no Ann Rheum Dis (2015)

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study

por Kavanaugh, Arthur, Husni, M. Elaine, Harrison, Diane D., Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H., Hsia, Elizabeth C.
Publicado no Arthritis Rheumatol (2017)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial

por Conaghan, Philip G, Emery, Paul, Østergaard, Mikkel, Keystone, Edward C, Genovese, Mark C, Hsia, Elizabeth C, Xu, Weichun, Rahman, Mahboob U
Publicado em 2011

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study...

por Mease, Philip, Elaine Husni, M., Chakravarty, Soumya D., Kafka, Shelly, Parenti, Dennis, Kim, Lilianne, Hung Lo, Kim, Hsia, Elizabeth C., Kavanaugh, Arthur
Publicado no ACR Open Rheumatol (2020)

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

por Kirkham, Bruce W, Wasko, Mary Chester, Hsia, Elizabeth C, Fleischmann, Roy M, Genovese, Mark C, Matteson, Eric L, Liu, Hongjuan, Rahman, Mahboob U
Publicado em 2014

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: res...

por Mease, Philip, Husni, M. Elaine, Kafka, Shelly, Chakravarty, Soumya D., Harrison, Diane D., Lo, Kim Hung, Xu, Stephen, Hsia, Elizabeth C., Kavanaugh, Arthur
Publicado no Arthritis Res Ther (2020)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis

por Husni, M. Elaine, Kavanaugh, Arthur, Murphy, Frederick, Rekalov, Dmytro, Harrison, Diane D., Kim, Lilianne, Lo, Kim Hung, Leu, Jocelyn H., Hsia, Elizabeth C.
Publicado no Arthritis Care Res (Hoboken) (2020)

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, rand...

por Smolen, Josef S, Kay, Jonathan, Doyle, Mittie, Landewé, Robert, Matteson, Eric L, Gaylis, Norman, Wollenhaupt, Jürgen, Murphy, Frederick T, Xu, Stephen, Zhou, Yiying, Hsia, Elizabeth C
Publicado no Arthritis Res Ther (2015)

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, doub...

por Smolen, Josef S, Kay, Jonathan, Landewé, Robert B M, Matteson, Eric L, Gaylis, Norman, Wollenhaupt, Jurgen, Murphy, Frederick T, Zhou, Yiying, Hsia, Elizabeth C, Doyle, Mittie K
Publicado em 2012

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial

por Helliwell, Philip S., Deodhar, Atul, Gottlieb, Alice B., Boehncke, Wolf-Henning, Xu, Xie L., Xu, Stephen, Wang, Yuhua, Hsia, Elizabeth C., Gladman, Dafna D., Ritchlin, Christopher T.
Publicado no Arthritis Care Res (Hoboken) (2020)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis

por Emery, Paul, van der Heijde, Désirée, Østergaard, Mikkel, Conaghan, Philip G, Genovese, Mark C, Keystone, Edward C, Fleischmann, Roy, Hsia, Elizabeth C, Xu, Weichun, Xu, Stephen, Rahman, Mahboob U
Publicado em 2011

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with ac...

por Rahman, Proton, Mease, Philip J., Helliwell, Philip S., Deodhar, Atul, Gossec, Laure, Kavanaugh, Arthur, Kollmeier, Alexa P., Hsia, Elizabeth C., Zhou, Bei, Lin, Xiwu, Shawi, May, Karyekar, Chetan S., Han, Chenglong
Publicado no Arthritis Res Ther (2021)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years

por Rahman, Mahboob U, Buchanan, Jacqui, Doyle, Mittie K, Hsia, Elizabeth C, Gathany, Timothy, Parasuraman, Shreekant, Aletaha, Daniel, Matteson, Eric L, Conaghan, Philip G, Keystone, Edward, van der Heijde, Désireé, Smolen, Josef S
Publicado em 2011

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, plac...

por Mease, Philip J, Gladman, Dafna D, Deodhar, Atul, McGonagle, Dennis G, Nash, Peter, Boehncke, Wolf-Henning, Gottlieb, Alice, Xu, Xie L, Xu, Stephen, Hsia, Elizabeth C, Karyekar, Chetan S, Helliwell, Philip S
Publicado no RMD Open (2020)

The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

por Furst, Daniel E., Kay, Jonathan, Wasko, Mary Chester, Keystone, Edward, Kavanaugh, Arthur, Deodhar, Atul, Murphy, Frederick T., Magnus, Jeanette H., Hsia, Elizabeth C., Hsu, Benjamin, Xu, Stephen, Rahman, Mahboob U., Doyle, Mittie K.
Publicado em 2013

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial

por Emery, Paul, Fleischmann, Roy M., Strusberg, Ingrid, Durez, Patrick, Nash, Peter, Amante, Eric Jason B., Churchill, Melvin, Park, Won, Pons‐Estel, Bernardo, Han, Chenglong, Gathany, Timothy A., Xu, Stephen, Zhou, Yiying, Leu, Jocelyn H., Hsia, Elizabeth C.
Publicado no Arthritis Care Res (Hoboken) (2016)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study...

por Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Soriano, Enrique R, Hsia, Elizabeth C, Kollmeier, Alexa P, Chakravarty, Soumya D, Zazzetti, Federico, Subramanian, Ramanand A, Xu, Xie L, Zuraw, Qing C, Sheng, Shihong, Jiang, Yusang, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Shawi, May, Karyekar, Chetan S, Deodhar, Atul
Publicado no RMD Open (2021)